EP-1167: Radiation therapy and breast reconstruction: outcomes and complications in our experience  by Gatti, M. et al.
S556                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
Conclusion: The 4.6% of local recurrence rate of PMRT cohort 
registered from 2005 to 2013 was lower than 13.1% (12/92) of 
non-PMRT cohort registered from 1990 to 2000. 
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Purpose or Objective: The aim of our study was to 
determine the impact of nodal status and other prognostic 
factors on clinical outcome of patients with breast cancer 
treated with surgery and adjuvant radiotherapy. 
 
Material and Methods: A total of 774 breast cancer patients 
treated between 2001 and 2013 were retrospectively 
analyzed. Qualitative and quantitative characteristics were 
summarized as frequencies and percentages, average and 
standard deviations. The rates of Overall Survival (OS), 
disease free survival (DFS), and loco-regional recurrence (LR) 
were calculated at 36 and 60 months with the Kaplan-Meier 
method. Multivariate analysis was also performed and a p 
value of 0.05 was considered statistically significant. 
 
Results: We identified 774 patients treated with adjuvant RT 
of which 595 patients (75.4%) without nodal involvement 
(pN0), 118 (14.9%) pN1-3 and 61 (7.75%) with more than 3 
positive lymph nodes (pN>3). In our sample, supra-clavicular 
region was irradiated in 62 patients (13 pN>3, 17 pN1-3, 32 
pN0). Median follow-up was 36 months (range 1-144 months). 
There were 14 cases of LR, of which 13 in pN0 and 1 in pN1-3 
patients. A total of 31 patients developed distant metastases 
(48.4% in pN0, 19.4% in pN1-3, 32.2% in pN>3 group). The 
mortality rate was of 2.8% (68.1% pN0, 18.2% pN1-3 and 
13.6% pN>3). There were no statistically significant 
differences in terms of OS, DFS and MFS among the three 
treatment groups. Multivariate analysis showed that clinical 
outcomes were significantly correlated with margin status (p-
value: 0.00), T-stage (p-value: 0.053), Her2-neu gene 
amplification (p-value: 0.00), Ki-67 (p-value: 0.00) and SCRT 
(p-value:0.00). Variables such as age, surgery, ER and PgR 
expression and grading, were not significant. 
 
Conclusion: In our study we observed higher rates of events 
in pN0 and pN1-3 patients, but none statistically significance 
was demonstrated between pN0, pN1-3 and pN>3 in terms of 
OS, DFS and MFS. Furthermore pN0 was in this experience the 
bigger group and this certainly influenced statistical analysis. 
In breast cancer, nodal status plays a key role both in the 
prognostic evaluation and in the therapeutic choice, and the 
clinical outcome of patients pN1-3 is comparable to pN>3 
patients; so in this group (pN1-3) it is also necessary the 
evaluation of other prognostic factors such as receptor 
status, Ki 67 and surgical margins. Nodal status alone seems 
incapable to really guide treatment choice, with particular 
regard to the SCRT appropriateness.  
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Purpose or Objective: The aim of this study was to evaluate 
treatment related complications and patient satisfaction in 
women with locally advanced breast cancer who received 
post-mastectomy radiation therapy after breast 
reconstruction. 
Material and Methods: Between 2009 and 2014, 65 patients, 
median age 48 years, with locally advanced breast cancer 
who underwent mastectomy with breast reconstruction in the 
same time, received post-mastectomy radiation therapy. Two 
patients received excision of local recurrence, 46 patients 
nipple sparing mastectomy, 10 skin sparing mastectomy and 7 
modified radical mastectomy. Post-mastectomy radiation 
therapy was delivered to the chest wall with a dose of 50 Gy 
in 25 fractions over 5 weeks (57 with 3Dconformal RT and 8 
with tomotherapy). 
 
Results: A patient interrupted radiation therapy to 20 Gy for 
severe acute toxicity with rejection of implants (delayed 
removal of the prosthesis). Acute dermal toxicity G2 for 
erythema, telangiectasia (1 patient) and edema was relieved 
in 26 patients, G1 toxicity in 36 patients, G0 in 2 patients and 
G3 in 1 patient. Two patients in systemic progression were 
not considered for local evaluation. At median follow-up of 
35 months: 43 patients presented late toxicity G1 due to 
hyperpigmentation, edema, periprothetic fibrosis. 7 patients 
referred sense of tension or pain and not satisfaction about 
the final aesthetic result. Two patients presented arm 
lymphedema. Two patients received replacing of the 
implants after 36 months due to contraction, encapsulation, 
dislocation, swelling. 
 
Conclusion: Radiotherapy can be safely delivered after 
breast reconstruction, with a low complication rate and good 
patient satisfaction. Further randomized studies are needed 
to better define the optimal management of breast 
reconstruction and post-mastectomy radiation therapy. 
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Purpose or Objective: The impact of adjuvant therapy on 
the surgical outcomes following breast reconstruction is 
poorly understood. The purpose of this work is to evaluate 
surgical outcomes following autologous and prosthetic 
reconstruction in the setting of post-mastectomy radiation 
therapy (PMRT) and adjuvant chemotherapy. We assessed the 
outcome and complications of irradiated patients in our 
department. 
 
Material and Methods: From May 2015 to July 2015 we 
analyzed acute, late toxicity and cosmetic results of 76 
patients with a median age of 50 ± 10 years undergoing 
mastectomy with immediate recostruction with prosthesis 
(79.7%), autologous technique (7.2%) or expander-implant 
(13%) following adjuvant radiotherapy. 24 patients underwent 
to Nac- Sparing Mastectomy, 10 of witch with periareolar 
pexy. 31 patients underwent to Skin reducing Mastectomy 
and 5 patients to Skin Sparing Mastectomy. The radiotherapy 
dose was 50 Gy to chest wall and supraclavicular limphnodes 
when indicated with 6 MV X-ray delivered with Linac (60pt), 
or with tomotherapy (16pt). 
 
Results: With a median follow-up of 25±24 months utilizing 
RTOG toxicity scale we observed a grade I acute toxicity in 
74.6% of patients, grade II in 6% of patients while in 19.4% of 
patients was not observed any sign of toxicity. Late toxicity 
was not observed in 68.7% of patients while in 28.4% of 
patients a grade I late toxicity was noted. No post-operative 
complications was observed in 62.3% of patients while in 
15.9% a capsular contracture was responsible in 20.3% of 
patients of explantation of prosthesis. None of patients 
developed post-operative skin ulcers. Cosmetic results was 
analyzed with Harvard Scale and was excellent in 4.5% of 
patients, good in 32.8%, fair in 16.4% and poor in 46.3%. The 
chi-test showed no correlation between early or late toxicity 
or cosmetics results with type of surgery (p>0.1). Univariate 
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analysis showed no relationship between cosmetic result and 
age (p>0.13). 
 
Conclusion: Our experiences is limited to a low number of 
cases but confirm that adjuvant radiotherapy is not 
controindicated when reconstructive surgery is expected. The 
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Purpose or Objective: To report 2-years toxicity and clinical 
results of hypofractionated simultaneous integrated boost 
(SIB) tecnique with Volumetric Modulated Arc Therapy 
(VMAT) as adjuvant treatment after breast-conserving 
surgery. 
 
Material and Methods: Patients presenting early-stage breast 
cancer were enrolled in a phase II trial. Eligibility criteria: 
age>18 years, invasive cancer or DCIS, Stage I-II (T<3 cm and 
N≤3), breast-conserving surgery without oncoplastic 
reconstruction, any systemic therapy was allowed in 
neoadjuvant or adjuvant setting. All patients underwent 
VMAT-SIB technique to irradiate the whole breast and the 
tumor bed. Doses to whole breast and surgical bed were 
40.5Gy and 48Gy, respectively, delivered in 15 fractions over 
3 weeks. Acute and late skin toxicities were recorded based 
on RTOG scoring criteria and CTCAE v. 4.0, respectively. 
Cosmetic outcome was assessed as excellent/good or 
fair/poor, according to the Harvard scale. 
 
Results: The present study focused on long-term results of a 
cohort of 144 patients with a minimum follow-up of 24 
months (median 37, range 24-55 months). Median age was 62 
y.o. (range 30-88). At one year, the highest reported skin 
toxicity was G1, in 14% of the patients; this data dropped to 
4% at the last follow-up, after more than 2 years. Breast pain 
was recorded in 21.6% of the patients 6 months after 
treatment, while it was present in 3.5% of the patients at the 
last follow-up, showing a significant improvement with time. 
No correlation with liponecrosis as recorded from ultrasound 
exam, nor with dosimetric data. Skin toxicity was correlated 
with breast volume. No pulmonary or cardiological toxicities 
were recorded. After an early evaluation of clinical 
outcomes, only one case presented disease relapse, as liver 
metastases. 
 
Conclusion: The hypofractionated VMAT-SIB course as 
adjuvant treatment after breast-conserving surgery showed 
to be safe and effective with optimal local control. This 
approach requires validation with long-term follow-up data. 
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Purpose or Objective: To investigate the impact of the boost 
dose escalation on ipsilateral breast tumor recurrence (IBTR), 
for breast cancer patients with involved surgical margins 
after breast conserving surgery. 
 
Material and Methods: Between January 1998 and December 
2010 at Asan Medical center, among 4275 breast cancer 
patients who were treated with breast conserving therapy 
(BCT), a total 192 patients were treated with boost dose over 
10 Gy for involved resection margin. We retrospectively 
analyzed the outcomes in 192 patients who had whole breast 
irradiation of 50.4 Gy followed by median boost dose 15.0 Gy 
(range, 12 - 16 Gy) for breast cancer with involved resection 
margin. Surgery preceded referral for radiotherapy with a 1-2 
mm margin of macroscopically normal tissue. The resection 
margins were evaluated by pathologist for the presence of 
invasive carcinoma or ductal carcinoma in situ at the inked 
margin. Neoadjuvant chemotherapy was done in 3 patients 
(1.6 %). Adjuvant chemotherapy was given in 93 patients 
(48.4%). 157 patients (81.8%) received systemic hormone 
therapy. The median age was 46 years (range, 25-73 years). 
182 patients (94.8%) were stage 0 to II and 10 patients (5.2%) 
with stage III breast cancer were also included. The boost 
dose delivered with electrons or tangential fields given in 
daily fractions of 1.5 to 2.5 Gy. The boost volume was 
described as the site of the primary tumor with a margin of 
1.5 cm to the field borders after breast conserving surgery. 
 
Results: The median follow-up duration for all patients was 
6.7 years. IBTR were considered as any local failures on 
ipsilateral breast regardless of the location. The 5-year 
cumulative risk of ipsilateral breast tumor recurrence as a 
first event was 5.4%. The 5-year local relapse free survival 
(LRFS) was 94.4%. IBTR occurred as a first failure in 13 of 192 
patients. In boost field recurrences were found in 11 patients 
(85%). 5 patients (39 %) were out-of boost field failures and 3 
of them were both failures. On univariate analysis, age, cell 
type, pT stage, pN stage, extensive intraductal component 
(EIC), multiplicity and location of resection margin were 
prognostic factor for IBTR (p <0.05). In multivariate analysis 
only young age (<40 years old) and positive radial resection 
margin were unfavorable prognostic factor for LRFS (p 
=0.037, p=0.021 respectively). pT stage was marginally 
significant prognostic factor for IBTR. (p=0.088) 
 
Conclusion: Median boost dose of 15 Gy is comparable to 
historical boost research results for local control in breast 
cancer patients with involved resection margin after BCT. 
Young age (<40 years old) and positive radial resection 
margin rather than superficial or deep margin were important 
risk factors for ipsilateral breast tumor recurrence. More than 
80% of local recurrences were in boost field, more boost dose 
escalation needs to be considered. 
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Purpose or Objective: Cancer-related fatigue is one of most 
prevalent symptom among women submitted to radiotherapy 
(RT) for breast cancer (BC). Despite its prevalence the 
mechanism of onset is unknown still: one possible mechanism 
is activation of the immune system, through the mediation by 
proinflammatory cytokines interleukin (IL), IL1-b,, IL-6, and 
tumor necrosis factor-a (TNF-a) as host response to tissue 
damage determined by the radiant treatment. To purpose of 
this study was to determine the level of fatigue in a group of 
BC patients its relation to anxiety, depression, serum 
cytokines, cortisol and blood count levels 
 
Material and Methods: Between October 2013 and May 2015 
twenty-eight patients who received adjuvant RT after breast 
conserving surgery were studied. The patients' subjective 
feeling of fatigue intensity was measured according to with 
two standardized self-assessment instruments the Fatigue 
Assessment Questionnaire (FAQ) and a visual analog scale 
(VAS) on fatigue intensity before the start and weekly during 
RT, as well as 14 days and 3-6 and 12 months after RT. In 
addition, a differential blood cell count and the serum levels 
of the cytokines- IL1-b,, IL-6, and TNF-a, were determined in 
parallel to the fatigue assessments. 
 
